• Effect on the hypothalamic-pituitary-adrenal axis and effect on the calcium metabolism [ Time Frame: Week 4 and 8 ] [ Designated as safety issue: Yes ]
  

• Overall disease severity of the face and intertriginous areas according to the investigator´s global assessment of disease severity. [ Time Frame: Week 4 and 8 ] [ Designated as safety issue: No ]
  

Drug: Calcipotriol plus hydrocortisone (LEO 80190)
Once daily application

Inclusion Criteria:

• Clinical diagnosis of psoriasis vulgaris involving the face and the intertriginou areas
• Clinical diagnosis of psoriasis vulgaris on the trunk and/or limbs or earlier diagnosed with psoriasis vulgaris on the trunk and/or limbs
• An extent of psoriatic involvement on the face of at least 10 cm2 and on the intertriginous areas of at least 20 cm2
• Treatment areas (face and intertriginous) amenable to topical treatment with a maximum of 100g ointment per week
• Disease severity of the face and intertriginous areas graded as moderate, severe or very severe according to the investigator´s global assessment of disease severity
• Patients with a normal HPA axis function: serum cortisol concentration above 5 mcg/dl before ACTH (tetracosactid) injection and serum corticol concentration above 18 mcg/dl 30 min after ATCT (tetracosactid) injection
• Albumin corrected serum calcium within reference range
• Females of childbearing potential have to use a highly effective method of contraception during the study (hormonal contraceptives on oestrogen basis are not allowed)

Exclusion Criteria:

• A history of active allergy, asthma, allergic skin rash, or sensitivity to any medication (including ACTH/tetracosactid) or to any component of the formulations being tested
• Systemic treatment with all other therapies than biologicals, with a potential effect on psoriasis vulgaris (eg vitamin D analogues, retinoids, immunosuppressants) within 2 weeks prior to Visit 1
• Systemic treatment with corticosteroids within 12 weeks prior to Visit 1
• Systemic use uf biological treatments, whether marketed or not, directed against or with a potential effect on psoriasis vulgaris (eg. alefacept, efalizumab, etanercept, infliximab, adalimumab) within 12 weeks prior to Visit 1
• PUVA therapy or Grenz ray therapy within 4 weeks prior to Visit 1
• UVB therapy within 2 weeks prior to Visit 1
• Topical treatment with WHO group 2, 3 or 4 corticosteroids within 4 weeks prior to Visit 1
• Topical treatment with WHO group 1 corticosteroids within 2 weeks prior to Visit 1
• Any topical treatment of the face and intertriginous areas (except for emollients) within 2 weeks prior to Visit 1
• Oestrogen therapy or any other medication known to affect cortisol levels or HPA-axis integrity within 4 weeks prior to Visit 1
• Enzymatic inductors, systemic or topical cytochrome P450 inhibitors, hypoglycaemic sulfonamides or antidepressive medication within 4 weeks prior to Visit 1
• Current diagnosis of erythrodermic, exfoliative, guttate or pustular psoriasis
• Patients with any of the following conditions present on the treatment area: viral (e.g., herpes or varicella) lesions of the skin, fungal and bacterial skin infections, parasitic infections, skin manifestations in relation to syphilis or tuberculosis, rosacea, perioral dermatitis, acne vulgaris, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, acne rosacea, ulcers and wounds
• Other inflammatory skin diseases (e.g., seborrhoiec dermatitis, contact dermatitis and cutaneous mycosis) that may confound the evaluation of psorisis vulgaris on the face or on the intertriginous areas
• Planned exposure to sun, UVA or UVB during the study that may affect the psoriasis vulgaris
• Clinical signs or symptoms of Cushing´s disease or Addison's disease
• Known or suspected severe renal insufficiency or severe hepatic disorders
• Known or suspected disorders of calcium metabolism associated with hypercalcaemia
• Known or suspected endocrine disorder that may affect the results of the ACTH challenge test